An evaluation of the efficacy of curcumin for treating infantile hemangioma endothelial cells (HemECs) found that its 100 μM concentration exhibited a high inhibition activity for the proliferation capability of HemECs; as proven by positive annexin-V-FITC staining, caspase-3 activation, and the cleavage of poly(adenosine diphosphate-ribose) polymerase (PARP) in the treated cells, curcumin achieved low-micromolar IC50 (half maximal inhibitory concentration) and induced apoptosis in HemECs through the downregulation of myeloid cell leukemia-1 (MCL-1) and hypoxia-inducible factor 1a [18]. This evidence concerns the gene MCL1 and capillary hemangioma.